Cargando…

Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid

Bullous pemphigoid (BP) is an autoimmune blistering disease of elderly patients that has shown increasing incidence in the last decades. Higher prevalence of BP may be due to more frequent use of provoking agents, such as antidiabetic dipeptidyl peptidase-4 inhibitor (DPP4i) drugs. Our aim was to as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kinyó, Ágnes, Hanyecz, Anita, Lengyel, Zsuzsanna, Várszegi, Dalma, Oláh, Péter, Gyömörei, Csaba, Kálmán, Endre, Berki, Tímea, Gyulai, Rolland
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125701/ https://www.ncbi.nlm.nih.gov/pubmed/33925042 http://dx.doi.org/10.3390/jcm10091916

Ejemplares similares

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
por: Tasanen, Kaisa, et al.
Publicado: (2019)

Bullous pemphigoid associated with use of dipeptidyl peptidase-4 inhibitor
por: Kano, Yasuhiro, et al.
Publicado: (2022)

Bullous pemphigoid with dipeptidyl peptidase‐4 inhibitors: Clinical features and pathophysiology
por: Murakami, Takaaki, et al.
Publicado: (2019)

Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid()()
por: Gravani, Agoritsa, et al.
Publicado: (2021)

Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor – A case report
por: Karthik, S, et al.
Publicado: (2019)

Bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitors: A report of five cases
por: Yoshiji, Satoshi, et al.
Publicado: (2017)

Dipeptidyl Peptidase-4 Inhibitors Cause Bullous Pemphigoid in Diabetic Patients: Report of Two Cases
por: Pasmatzi, Efi, et al.
Publicado: (2011)

Congenital ichthyosis associated with Trichophyton rubrum tinea, imitating drug hypersensitivity reaction
por: Szlávicz, Eszter, et al.
Publicado: (2020)

The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study
por: Lambadiari, Vaia, et al.
Publicado: (2021)

Dipeptidyl Peptidase-4 Inhibitor-Related Bullous Pemphigoid: Clinical, Laboratory, and Histological Features, and Possible Pathogenesis
por: Hung, Chih-Tsung, et al.
Publicado: (2022)

Dipeptidyl-Peptidase 4 Inhibitor-Induced Variants of Bullous Pemphigoid: A Case Series of Four Patients
por: Balighi, Kamran, et al.
Publicado: (2022)

Lisinopril prevents bullous pemphigoid induced by dipeptidyl peptidase 4 inhibitors via the Mas receptor pathway
por: Nozawa, Keisuke, et al.
Publicado: (2023)

Dipeptidyl peptidase‐4 inhibitors‐associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients
por: Kawaguchi, Yohei, et al.
Publicado: (2018)

Bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication
por: Shinohara, Yasutake, et al.
Publicado: (2020)

Expression Patterns of Clock Gene mRNAs and Clock Proteins in Human Psoriatic Skin Samples
por: Németh, Viktória, et al.
Publicado: (2021)

Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180
por: Mai, Yosuke, et al.
Publicado: (2019)

The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study
por: Bukvić Mokos, Zrinka, et al.
Publicado: (2020)

Bullous Pemphigoid Associated with Dipeptidyl Peptidase 4 Inhibitors for the Treatment of Type 2 Diabetes: A Multicenter Study in Istanbul
por: Ugurer, Ece, et al.
Publicado: (2022)

Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
por: Iwamoto, Yuichiro, et al.
Publicado: (2022)

SARS‐CoV‐2 vaccine‐triggered conversion from systemic lupus erythematosus (SLE) to bullous SLE and dipeptidyl peptidase 4 inhibitors‐associated bullous pemphigoid
por: Nakahara, Yukiko, et al.
Publicado: (2022)

Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature
por: Mai, Yosuke, et al.
Publicado: (2018)

Bullous Pemphigoid Associated with the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin in a Patient with Liver Cirrhosis Complicated with Rapidly Progressive Hepatocellular Carcinoma
por: Harada, Masaru, et al.
Publicado: (2017)

Clinical Features and Outcomes of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid (DPP4i-Associated BP) in Thai Patients
por: Thewjitcharoen, Yotsapon, et al.
Publicado: (2020)

Dipeptidyl-peptidase IV inhibitor (DPP4i) confers increased odds of bullous pemphigoid even years after drug initiation
por: Kridin, Khalaf, et al.
Publicado: (2022)

Recalcitrant infantile bullous pemphigoid successfully treated with cyclosporine
por: Bar-Ilan, Efrat, et al.
Publicado: (2022)

Pemphigoid Nodularis Induced by Long-Term Use of Dipeptidyl Peptidase-4 Inhibitors
por: Norikawa, Natsumi, et al.
Publicado: (2023)

Serum autoantibodies against the extracellular region of α6β4 integrin in a patient with dipeptidyl peptidase-4 inhibitor–induced bullous pemphigoid
por: Yamashita, Chigusa, et al.
Publicado: (2021)

Bullous pemphigoid
por: Miyamoto, Denise, et al.
Publicado: (2019)

Bullous Pemphigoid and Other Pemphigoid Dermatoses
por: Pratasava, Valeryia, et al.
Publicado: (2021)

Results of a Primary Skin-Cancer-Prevention Campaign in Early Childhood on Sun-Related Knowledge and Attitudes in Southern Hungary
por: Horváth, Zsuzsanna, et al.
Publicado: (2021)

Resolution in bullous pemphigoid
por: Sadik, Christian D., et al.
Publicado: (2019)

Esophageal Bullous Pemphigoid
por: Castelo Branco, Catarina, et al.
Publicado: (2022)

Dyshidrosiform Bullous Pemphigoid
por: Cohen, Philip R.
Publicado: (2021)

A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors
por: Izumi, Kentaro, et al.
Publicado: (2019)

Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase‐4 inhibitors: A population‐based cohort study using Japanese Latter‐Stage Elderly Healthcare Database
por: Harano, Yumi, et al.
Publicado: (2023)

Cutaneous Dermatophytosis Mimicking Bullous Pemphigoid or Typical Bullous Pemphigoid and Tinea Incognito?
por: Andrés, Tirado-Sánchez, et al.
Publicado: (2019)

When Bullous Pemphigoid Is Not Bullous Pemphigoid: The Importance of Going Beyond Direct Immunofluorescence
por: Hopkins, Christina R, et al.
Publicado: (2022)

Ocular cicatricial pemphigoid following Dipeptidyl Peptidase-4 inhibitor use: A case report
por: Matsumoto, Akifumi, et al.
Publicado: (2023)

Hemizygous nonsense variant in the moesin gene (MSN) leads to a new autoimmune phenotype of Immunodeficiency 50
por: Kovács, András L., et al.
Publicado: (2022)

LOCALIZED FLEXURAL BULLOUS PEMPHIGOID
por: Mehta, Vandana, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_gruco8bo7c9tvl7e1v35beohim